Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

Neurochemical and Behavioral Effects of Ciproxifan, A Potent Histamine H3-Receptor Antagonist

X. Ligneau, J.-S. Lin, G. Vanni-Mercier, M. Jouvet, J. L. Muir, C. R. Ganellin, H. Stark, S. Elz, W. Schunack and J.-C. Schwartz
Journal of Pharmacology and Experimental Therapeutics November 1998, 287 (2) 658-666;
X. Ligneau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J.-S. Lin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Vanni-Mercier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Jouvet
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. L. Muir
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. R. Ganellin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. Stark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Elz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. Schunack
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J.-C. Schwartz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Ciproxifan, i.e., cyclopropyl-(4-(3-1H-imidazol-4-yl)propyloxy) phenyl) ketone, belongs to a novel chemical series of histamine H3-receptor antagonists. In vitro, it behaved as a competitive antagonist at the H3 autoreceptor controlling [3H]histamine release from synaptosomes and displayed similar Ki values (0.5–1.9 nM) at the H3 receptor controlling the electrically-induced contraction of guinea pig ileum or at the brain H3 receptor labeled with [125I]iodoproxyfan. Ciproxifan displayed at least 3-orders of magnitude lower potency at various aminergic receptors studied in functional or binding tests. In vivo, measurement of drug plasma levels, using a novel radioreceptor assay in mice receiving ciproxifan p.o. or i.v., led to an oral bioavailability ratio of 62%. Oral administration of ciproxifan to mice enhanced by ∼100% histamine turnover rate and steady state level oftele-methylhistamine with an ED50 of 0.14 mg/kg. Ciproxifan reversed the H3-receptor agonist induced enhancement of water consumption in rats with and ID50 of 0.09 ± 0.04 mg/kg, i.p. In cats, ciproxifan (0.15–2 mg/kg, p.o.) induced marked signs of neocortical electroencephalogram activation manifested by enhanced fast-rhythms density and an almost total waking state. In rats, ciproxifan enhanced attention as evaluated in the five-choice task performed using a short stimulus duration. Ciproxifan appears to be an orally bioavailable, extremely potent and selective H3-receptor antagonist whose vigilance- and attention-promoting effects are promising for therapeutic applications in aging disorders.

Footnotes

  • Send reprint requests to: Dr. Jean-Charles Schwartz, Unité de Neurobiologie et Pharmacologie Moléculaire (U.109), Centre Paul Broca de I’INSERM, 2ter rue d’Alésia, 75014 Paris, France.

  • 1 This work was supported by the Biomedical and Health Research Program EEC BMH4 CT96-0204 and the Direction des Recherches Etudes et Techniques (DRET 92/045).

  • Abbreviations:
    HA
    histamine
    t-MeHA
    tele-methylhistamine
    (R)α-MeHA
    (R)α-methylhistamine
    AUC
    area under the curve
    Cmax
    maximal concentration
    W
    wakefulness
    S1
    light slow wave sleep
    S2
    deep slow wave sleep
    PS
    paradoxical sleep
    EEG
    electroencephalogram
    • Received February 24, 1998.
    • Accepted June 7, 1998.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 287, Issue 2
1 Nov 1998
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Neurochemical and Behavioral Effects of Ciproxifan, A Potent Histamine H3-Receptor Antagonist
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Neurochemical and Behavioral Effects of Ciproxifan, A Potent Histamine H3-Receptor Antagonist

X. Ligneau, J.-S. Lin, G. Vanni-Mercier, M. Jouvet, J. L. Muir, C. R. Ganellin, H. Stark, S. Elz, W. Schunack and J.-C. Schwartz
Journal of Pharmacology and Experimental Therapeutics November 1, 1998, 287 (2) 658-666;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Neurochemical and Behavioral Effects of Ciproxifan, A Potent Histamine H3-Receptor Antagonist

X. Ligneau, J.-S. Lin, G. Vanni-Mercier, M. Jouvet, J. L. Muir, C. R. Ganellin, H. Stark, S. Elz, W. Schunack and J.-C. Schwartz
Journal of Pharmacology and Experimental Therapeutics November 1, 1998, 287 (2) 658-666;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • PST3093 Stimulates SERCA2a and Improves Cardiac Function
  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Ethnic Differences in N-Glucuronidation of Nicotine and Cotinine
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics